Aims The purpose of this analysis was to determine whether the efficacy of adenosine vs. placebo was dependent on the timing of reperfusion therapy in the second Acute Myocardial Infarction Study of Adenosine (AMISTAD-II).

Methods and results Patients presenting with ST-segment elevation anterior AMI were randomized to receive placebo vs. adenosine (50 or 70 µg/kg/min) for 3 h starting within 15 min of reperfusion therapy. In the present post hoc hypothesis generating study, the results were stratified according to the timing of reperfusion, i.e. ≥ or < the median 3.17 h, and by reperfusion modality. In patients receiving reperfusion <3.17 h, adenosine compared with placebo significantly reduced 1-month mortality (5.2 vs. 9.2%, respectively, P=0.014), 6-month mortality (7.3 vs. 11.2%, P=0.033), and the occurrence of the primary 6-month composite clinical endpoint of death, in-hospital CHF, or rehospitalization for CHF at 6 months (12.0 vs. 17.2%, P=0.022). Patients reperfused beyond 3 h did not benefit from adenosine.

Conclusion In this post hoc analysis, 3 h adenosine infusion administered as an adjunct to reperfusion therapy within the first 3.17 h onset of evolving anterior ST-segment elevation AMI enhanced early and late survival, and reduced the composite clinical endpoint of death or CHF at 6 months.

Introduction

The second Acute Myocardial Infarction Study of Adenosine (AMISTAD-II) trial demonstrated that high-dose intravenous adenosine as an adjunct to reperfusion therapy for acute anterior myocardial infarction (AMI) reduced myocardial infarct size (27% of the left ventricle in the placebo group vs. 11% in the high-dose adenosine group, P=0.023).1 The rate of occurrence, however, of the primary composite clinical endpoint of death, new onset congestive heart failure (CHF) beginning >24 h after randomization, or rehospitalization for CHF within 6 months were not statistically different between placebo (17.9%) and either the pooled-adenosine dose groups (16.3%), or separately the low-dose (50 µg/kg/min) or the high-dose (70 µg/kg/min) adenosine group (16.5 and 16.1%, respectively). Patients were enrolled in AMISTAD-II if reperfusion therapy [consisting of either thrombolysis or primary percutaneous coronary intervention (PCI)] was administered within 6 h of symptom onset. Given the well described impact of reperfusion delays on myocardial salvage and clinical outcomes2 and of the variability between PCI and thrombolytic therapy in achieving reperfusion success, the present post hoc subanalysis was performed to determine whether adenosine might have differential efficacy as a function of reperfusion time and modality.

Methods

The AMISTAD-II study was a double-blinded, placebo-controlled, randomized, multicentre, international study. Details of the methodology of the study have been described.1 Patients (n=2118), over 18 years or more, presenting with ongoing ischaemic pain for at least 30 min duration and with electrocardiographic evidence of an anterior ST-segment elevation MI [ST-elevation in at least two contiguous precordial leads or (presumed) new left bundle branch block], in whom reperfusion therapy was administered within 6 h of symptom onset, were randomized to receive either intravenous placebo, adenosine 50 µg/kg/min, or adenosine 70 µg/kg/min starting within 15 min of the start of fibrinolysis or prior to coronary intervention and continuing for 3 h thereafter.

Endpoints

The primary intention to treat composite clinical endpoint in AMISTAD-II was new onset in-hospital CHF occurring >24 h after initiation of reperfusion, rehospitalization for CHF, or death (from any cause) during the 6-month follow-up period. Six months was chosen to capture one long-term time point. CHF was found to be present if two of the following criteria were observed: new pulmonary oedema by chest X-ray in the absence of a non-cardiac cause, rales heard over one-third or more of the lung fields, pulmonary capillary wedge pressure >18 mmHg with a cardiac index <2.4 L/min/m2, dyspnea with PO2<80 mmHg or O2 saturation <90% without known pre-existing lung disease, and use of loop diuretics to treat pulmonary congestion. Secondary endpoints included death at 1-month, the individual components of the primary endpoint, and myocardial infarct size [measured by technetium-99 m sestamibi single-photon emission computed tomography (SPECT)] 120 to 216 hours after randomisation in a 266-patient substudy (243 of whom had suitable images for quantitative analysis).

For the present analysis, these endpoints were analysed according to: (i) time to initiating reperfusion therapy (less than or greater than or equal to the median of 3.17 h); and (ii) the type of reperfusion therapy used (thrombolysis vs. PCI). A total of 33 of 2118 patients (1.6%) received neither thrombolysis nor primary angioplasty, and were not included in the present analysis. As in the original study, outcomes were compared for patients in the placebo, pooled-adenosine, low-dose and high-dose adenosine groups.

Statistical analysis

Baseline features were compared with either the Fisher's exact test for categorical variables or t-test for continuous variables. For clinical outcomes, Kaplan–Meier estimates were generated and compared with the log rank test. Myocardial infarct size data were summarized as median (25th percentile, 75th percentile) and compared using the Kruskal–Wallis test. Formal interaction testing was performed to evaluate the impact of: (i) treatment assignment and reperfusion modality on mortality and infarct size; and (ii) treatment assignment and time to reperfusion (as a continuous variable) on the 6-month primary composite endpoint. Interaction testing was performed by creating multivariable models (Cox proportional hazards regression for time-to-event data, and linear regression for infarct size), with significant levels to enter and stay of 0.05 and 0.10, respectively. In addition to treatment assignment, time to reperfusion and reperfusion modality, the following variables were entered into the models: age, gender, prior MI, and Killip class 1 vs. 2–4. All analyses were intented for a treatment, and all P-values were two-sided. A P-value of <0.05 was considered statistically significant.

Results

Baseline features and outcomes of the study population stratified by the initiation of reperfusion time are shown in Table 1. Compared with patients receiving initiation of early reperfusion therapy (<3.17 h), those reperfused later (≥3.17 h) were slightly older, had more diabetes, and were less likely to have had a prior MI. Patients who were reperfused early were less likely to die and develop heart failure compared with patients reperfused late (Table 1). There were no statistically significant differences in the baseline features of the placebo- vs. adenosine-treated patients in either the early group (reperfusion <3.17 h) or the later group (reperfusion ≥3.17 h) (Table 2).

Table 1

Baseline features and outcomes stratified by the initiation of early reperfusion therapy (<median of 3.17 h) vs. late reperfusion therapy (≥median)

 Early (n=1066) Late (n=1018) P-value 
Baseline features    
 Age (years) 59.2±12.6 61.7±12.8 <0.0001 
 Male 76.9% (820/1066) 70.2% (715/1018) 0.0006 
 Diabetes mellitus 14.0% (149/1061) 19.1% (192/1004) 0.002 
 Prior MI 14.4% (152/1055) 11.1% (112/1009) 0.025 
 Killip class 2–4 15.0% (160/1066) 17.2% (175/1018) 0.189 
 Symptom onset to treatment (hours) 2.15±0.66 4.48±0.92 <0.0001 
  Thrombolytic therapy (hours) 2.11±0.70 4.55±0.86 <0.0001 
  Primary angioplasty (hours) 2.41±0.67 4.55±0.94 <0.0001 
Outcomes    
 Death at 1 month 6.5% 9.6% 0.008 
 Composite 6-month endpoint 13.7% 20.2% <0.0001 
  Death 8.6% 13.1% 0.0009 
  In-hospital CHF 3.5% 4.8% 0.15 
  Rehospitalization for CHF 3.1% 5.8% 0.005 
 Infarct size (% of left ventricle) 24.0 (2.0, 42.0) (n=133) 19.0 (1.0, 39.0) (n=108) 0.64 
 Early (n=1066) Late (n=1018) P-value 
Baseline features    
 Age (years) 59.2±12.6 61.7±12.8 <0.0001 
 Male 76.9% (820/1066) 70.2% (715/1018) 0.0006 
 Diabetes mellitus 14.0% (149/1061) 19.1% (192/1004) 0.002 
 Prior MI 14.4% (152/1055) 11.1% (112/1009) 0.025 
 Killip class 2–4 15.0% (160/1066) 17.2% (175/1018) 0.189 
 Symptom onset to treatment (hours) 2.15±0.66 4.48±0.92 <0.0001 
  Thrombolytic therapy (hours) 2.11±0.70 4.55±0.86 <0.0001 
  Primary angioplasty (hours) 2.41±0.67 4.55±0.94 <0.0001 
Outcomes    
 Death at 1 month 6.5% 9.6% 0.008 
 Composite 6-month endpoint 13.7% 20.2% <0.0001 
  Death 8.6% 13.1% 0.0009 
  In-hospital CHF 3.5% 4.8% 0.15 
  Rehospitalization for CHF 3.1% 5.8% 0.005 
 Infarct size (% of left ventricle) 24.0 (2.0, 42.0) (n=133) 19.0 (1.0, 39.0) (n=108) 0.64 
Table 2

Baseline features in patients receiving reperfusion therapy in placebo vs. pooled-adenosine group

 Placebo Pooled-adenosine P-value 
Early (<median of 3.17 h) (n=350) (n=716)  
 Age (years) 59.1±13.0% 59.2±12.4% 0.841 
 Male 75.4% (264/350) 77.7% (556/716) 0.439 
 Diabetes mellitus 16.1% (56/348) 13.0% (93/713) 0.188 
 Hypertension 48.7% (169/347) 45.7% (321/703) 0.358 
 Prior MI 11.6% (40/345) 15.8% (112/710) 0.076 
 Killip class 2–4 13.7% (48/350) 15.6% (112/716) 0.465 
 Symptom onset to treatment (hours) 2.18±0.64 2.13±0.66 0.249 
Late (>median of 3.17 h) (n=341) (n=677)  
 Age (years) 61.1±13.2% 62.0±12.7% 0.265 
 Male 72.4% (247/341) 69.1% (468/677) 0.309 
 Diabetes mellitus 16.0% (54/338) 20.7% (138/666) 0.075 
 Hypertension 52.7% (177/336) 55.4% (372/671) 0.421 
 Prior MI 11.9% (40/337) 10.7% (72/672) 0.596 
 Killip class 2–4 16.1% (55/341) 17.7% (120/677) 0.539 
 Symptom onset to treatment (hours) 4.52±0.95 4.46±0.91 0.367 
 Placebo Pooled-adenosine P-value 
Early (<median of 3.17 h) (n=350) (n=716)  
 Age (years) 59.1±13.0% 59.2±12.4% 0.841 
 Male 75.4% (264/350) 77.7% (556/716) 0.439 
 Diabetes mellitus 16.1% (56/348) 13.0% (93/713) 0.188 
 Hypertension 48.7% (169/347) 45.7% (321/703) 0.358 
 Prior MI 11.6% (40/345) 15.8% (112/710) 0.076 
 Killip class 2–4 13.7% (48/350) 15.6% (112/716) 0.465 
 Symptom onset to treatment (hours) 2.18±0.64 2.13±0.66 0.249 
Late (>median of 3.17 h) (n=341) (n=677)  
 Age (years) 61.1±13.2% 62.0±12.7% 0.265 
 Male 72.4% (247/341) 69.1% (468/677) 0.309 
 Diabetes mellitus 16.0% (54/338) 20.7% (138/666) 0.075 
 Hypertension 52.7% (177/336) 55.4% (372/671) 0.421 
 Prior MI 11.9% (40/337) 10.7% (72/672) 0.596 
 Killip class 2–4 16.1% (55/341) 17.7% (120/677) 0.539 
 Symptom onset to treatment (hours) 4.52±0.95 4.46±0.91 0.367 

Impact of reperfusion time

In patients who received initiation of reperfusion therapy early (<3.17 h), mortality at both 1 month and 6 months as well as the primary composite clinical endpoint at 6 months were significantly reduced in the pooled-adenosine group compared with placebo, with no clear distinction in efficacy between the low-dose and high-dose adenosine dose regimens (Table 3). A non-significant trend was present towards reduced infarct size in the high-dose adenosine group (n=49, P=0.143). In contrast to the beneficial effects of adenosine in the early reperfusion group, adenosine did not improve clinical outcomes in patients reperfused later (Table 3), though a trend was present for reduced infarct size in the pooled-adenosine group (P=0.082) and the high-dose adenosine group (n=34, P=0.081). The interaction between treatment and time to reperfusion as a continuous variable was significant at the P=0.045 level after adjusting for other covariates.

Table 3

Impact of adenosine in patients receiving initiation of early reperfusion therapy (< median of 3.17 h) vs. late reperfusion therapy (≥median)

 Placebo Pooled-adenosine P-value Pooled vs. placebo Adenosine 50 µg/kg/min Adenosine 70 µg/kg/min 
Early reperfusion therapy      
n 350 716  350 366 
 Death at 1 month 9.2% 5.2% 0.014 5.1%* 5.2%* 
 Composite 6-month endpoint 17.2% 12.0% 0.022 10.9%** 13.2% 
  Death 11.2% 7.3% 0.033 7.2%*** 7.4%***** 
  In-hospital CHF 4.0% 3.2% 0.59 1.7%**** 4.6% 
  Rehospitalization for CHF 3.8% 2.8% 0.42 3.3% 2.3% 
 Infarct size (% of left ventricle) 24.0 (4.0, 43.0) (n=41) 21.5 (0.5, 42.0) (n=92) 0.35 27.0 (7.0, 42.0) (n=43) 11.0 (0.0, 43.0) (n=49) 
Late reperfusion therapy      
n 341 677  345 332 
 Death at 1 month 9.1% 9.9% 0.66 12.2% 7.5% 
 Composite 6-month endpoint 19.1% 20.7% 0.49 22.7% 18.7% 
  Death 12.6% 13.3% 0.74 13.9% 12.7% 
  In-hospital CHF 4.1% 5.2% 0.54 6.4% 3.9% 
  Rehospitalization for CHF 5.8% 5.7% 0.98 5.3% 6.2% 
 Infarct size (% of left ventricle) 34.0 (0.0, 50.0) (n=35) 14.0 (1.0, 36.0) (n=73) 0.08 16.0 (4.0, 38.0) (n=39) 11.5***** (0.0, 31.0) (n=34) 
 Placebo Pooled-adenosine P-value Pooled vs. placebo Adenosine 50 µg/kg/min Adenosine 70 µg/kg/min 
Early reperfusion therapy      
n 350 716  350 366 
 Death at 1 month 9.2% 5.2% 0.014 5.1%* 5.2%* 
 Composite 6-month endpoint 17.2% 12.0% 0.022 10.9%** 13.2% 
  Death 11.2% 7.3% 0.033 7.2%*** 7.4%***** 
  In-hospital CHF 4.0% 3.2% 0.59 1.7%**** 4.6% 
  Rehospitalization for CHF 3.8% 2.8% 0.42 3.3% 2.3% 
 Infarct size (% of left ventricle) 24.0 (4.0, 43.0) (n=41) 21.5 (0.5, 42.0) (n=92) 0.35 27.0 (7.0, 42.0) (n=43) 11.0 (0.0, 43.0) (n=49) 
Late reperfusion therapy      
n 341 677  345 332 
 Death at 1 month 9.1% 9.9% 0.66 12.2% 7.5% 
 Composite 6-month endpoint 19.1% 20.7% 0.49 22.7% 18.7% 
  Death 12.6% 13.3% 0.74 13.9% 12.7% 
  In-hospital CHF 4.1% 5.2% 0.54 6.4% 3.9% 
  Rehospitalization for CHF 5.8% 5.7% 0.98 5.3% 6.2% 
 Infarct size (% of left ventricle) 34.0 (0.0, 50.0) (n=35) 14.0 (1.0, 36.0) (n=73) 0.08 16.0 (4.0, 38.0) (n=39) 11.5***** (0.0, 31.0) (n=34) 

*P=0.04 vs. placebo; **P=0.015 vs. placebo; ***P=0.065 vs. placebo; ****P=0.07 vs. placebo; *****P=0.08 vs. placebo.

Impact of reperfusion modality

As shown in Table 4, patients treated with primary PCI compared with thrombolytic therapy were slightly younger, had more diabetes, and were less likely to have had a prior MI. As expected, patients treated with primary PCI rather than thrombolytic therapy had lower rates of death at 1 month, composite clinical 6-month endpoint, less death at 6 months and less in-hospital CHF (Table 4).

Table 4

Baseline features and outcomes stratified by treatment with thrombolytic therapy or primary angioplasty

 Thrombolytic therapy (n=1234) Primary angioplasty (n=851) P-value 
Baseline features    
 Age (years) 60.9±12.8 59.7±12.7 0.043 
 Male 70.5% (870/1234) 78.1% (665/851) <0.0001 
 Diabetes mellitus 14.2% (173/1220) 19.9% (168/846) 0.0007 
 Prior MI 14.2% (174/1226) 10.7% (90/839) 0.022 
 Killip class 2–4 17.3% (213/1234) 14.3% (122/851) 0.079 
 Symptom onset to treatment (hours) 3.27±1.44 3.33±1.37 0.338 
Outcomes    
 Death at 1 month 10.6% 4.4% <0.0001 
 Composite 6-month endpoint 20.5% 11.7% <0.0001 
  Death 14.0% 6.2% <0.0001 
  In-hospital CHF 4.9% 2.9% 0.025 
  Rehospitalization for CHF 4.6% 4.1% 0.592 
 Infarct size (% of left ventricle) 21.0 (6.0, 42.0) (n=77) 19.0 (0.0, 41.0) (n=164) 0.415 
 Thrombolytic therapy (n=1234) Primary angioplasty (n=851) P-value 
Baseline features    
 Age (years) 60.9±12.8 59.7±12.7 0.043 
 Male 70.5% (870/1234) 78.1% (665/851) <0.0001 
 Diabetes mellitus 14.2% (173/1220) 19.9% (168/846) 0.0007 
 Prior MI 14.2% (174/1226) 10.7% (90/839) 0.022 
 Killip class 2–4 17.3% (213/1234) 14.3% (122/851) 0.079 
 Symptom onset to treatment (hours) 3.27±1.44 3.33±1.37 0.338 
Outcomes    
 Death at 1 month 10.6% 4.4% <0.0001 
 Composite 6-month endpoint 20.5% 11.7% <0.0001 
  Death 14.0% 6.2% <0.0001 
  In-hospital CHF 4.9% 2.9% 0.025 
  Rehospitalization for CHF 4.6% 4.1% 0.592 
 Infarct size (% of left ventricle) 21.0 (6.0, 42.0) (n=77) 19.0 (0.0, 41.0) (n=164) 0.415 

Randomization to adenosine rather than to placebo resulted in fewer deaths at 1 month and in strong trends towards less death at 6 months among patients treated with thrombolytic therapy early (Table 5). Adenosine (especially high-dose) also resulted in a reduction in infarct size in early lytic-treated patients. In contrast, patients treated with thrombolytic therapy later (Table 5) than the median time of 3.17 h had similar clinical outcomes with adenosine and placebo. Patients treated with early primary PCI had a non-significant trend towards lower death rates when they received adenosine (Table 6). There was no evidence that adenosine clinically benefited patients treated with late PCI (Table 6). By formal interaction testing, however, the impact of adenosine randomization was independent of reperfusion modality with regard to mortality (P=0.70) and infarct size (P=0.35).

Table 5

Impact of adenosine in patients receiving thrombolytic therapy early (<median of 3.17 h) vs. late (≥median)

 Placebo Pooled-adenosine P-value Pooled vs. placebo Adenosine 50 µg/kg/min Adenosine 70 µg/kg/min 
Early reperfusion therapy      
n 213 423  212 211 
 Death at 1 month 12.7% 7.6% 0.04 6.6%* 8.5% 
 Composite 6-month endpoint 21.2% 14.9% 0.055 12.8%** 17.1% 
  Death 15.5% 10.7% 0.08 9.5%*** 11.9% 
  In-hospital CHF 4.2% 3.5% 0.66 1.9% 5.2% 
  Rehospitalization for CHF 3.8% 2.6% 0.44 3.0% 2.1% 
 Infarct size (% of left ventricle) 36.5 (13.5, 50.5) (n=16) 17.0 (1.0, 42.0) (n=35) 0.054 32.0 (15.0, 46.0) (n=17) 8.0**** (0.0, 26.0) (n=18) 
Late reperfusion therapy      
n 198 399  195 204 
 Death at 1 month 11.6% 12.0% 0.86 15.9% 8.3% 
 Composite 6-month endpoint 23.3% 24.6% 0.66 28.7% 20.6% 
  Death 15.7% 15.5% 1.00 17.9% 13.2% 
  In-hospital CHF 5.1% 6.8% 0.47 8.2% 5.4% 
  Rehospitalization for CHF 6.8% 6.3% 0.84 5.5% 6.9% 
 Infarct size (% of left ventricle) 34.0 (0.0, 48.0) (n=11) 15.0 (9.0, 23.0) (n=15) 0.32 12.0 (9.0, 23.0) (n=7) 19.0 (6.5, 30.0) (n=8) 
 Placebo Pooled-adenosine P-value Pooled vs. placebo Adenosine 50 µg/kg/min Adenosine 70 µg/kg/min 
Early reperfusion therapy      
n 213 423  212 211 
 Death at 1 month 12.7% 7.6% 0.04 6.6%* 8.5% 
 Composite 6-month endpoint 21.2% 14.9% 0.055 12.8%** 17.1% 
  Death 15.5% 10.7% 0.08 9.5%*** 11.9% 
  In-hospital CHF 4.2% 3.5% 0.66 1.9% 5.2% 
  Rehospitalization for CHF 3.8% 2.6% 0.44 3.0% 2.1% 
 Infarct size (% of left ventricle) 36.5 (13.5, 50.5) (n=16) 17.0 (1.0, 42.0) (n=35) 0.054 32.0 (15.0, 46.0) (n=17) 8.0**** (0.0, 26.0) (n=18) 
Late reperfusion therapy      
n 198 399  195 204 
 Death at 1 month 11.6% 12.0% 0.86 15.9% 8.3% 
 Composite 6-month endpoint 23.3% 24.6% 0.66 28.7% 20.6% 
  Death 15.7% 15.5% 1.00 17.9% 13.2% 
  In-hospital CHF 5.1% 6.8% 0.47 8.2% 5.4% 
  Rehospitalization for CHF 6.8% 6.3% 0.84 5.5% 6.9% 
 Infarct size (% of left ventricle) 34.0 (0.0, 48.0) (n=11) 15.0 (9.0, 23.0) (n=15) 0.32 12.0 (9.0, 23.0) (n=7) 19.0 (6.5, 30.0) (n=8) 

*P=0.04 vs. placebo; **P=0.02 vs. placebo; ***P=0.06 vs. placebo; ****P=0.004 vs. placebo.

Table 6

Impact of adenosine in patients receiving primary PCI early (<median of 3.17 h) vs. late (≥median)

 Placebo Pooled-adenosine P-value Pooled vs. placebo Adenosine 50 µg/kg/min Adenosine 70 µg/kg/min 
Early reperfusion therapy      
n 137 293  138 155 
 Death at 1 month 3.7% 1.7% 0.21 2.9% 0.6%* 
 Composite 6-month endpoint 11.0% 7.9% 0.27 8.0% 7.8% 
  Death 4.4% 2.4% 0.25 3.6% 1.3% 
  In-hospital CHF 3.6% 2.7% 0.56 1.4% 3.9% 
  Rehospitalization for CHF 3.8% 3.1% 0.71 3.7% 2.6% 
 Infarct size (% of left ventricle) 16.0 (3.0, 37.0) (n=25) 24.0 (0.0, 43.0) (n=57) 0.847 24.5 (0.0, 39.0) (n=26) 24.0 (0.0, 49.0) (n=31) 
Late reperfusion therapy      
n 143 278  150 128 
 Death at 1 month 5.6% 6.9% 0.61 7.4% 6.3% 
 Composite 6-month endpoint 13.3% 15.2% 0.60 14.8% 15.6% 
  Death 8.4% 10.1% 0.57 8.7% 11.7% 
  In-hospital CHF 2.8% 2.9% 1.00 4.0% 1.6% 
  Rehospitalization for CHF 4.4% 5.0% 0.77 5.0% 5.0% 
 Infarct size (% of left ventricle) 27.5 (3.5, 50.0) (n=24) 13.5 (0.0, 37.0) (n=58) 0.136 22.5 (2.0, 38.5) (n=32) 8.5 (0.0, 31.0) (n=26) 
 Placebo Pooled-adenosine P-value Pooled vs. placebo Adenosine 50 µg/kg/min Adenosine 70 µg/kg/min 
Early reperfusion therapy      
n 137 293  138 155 
 Death at 1 month 3.7% 1.7% 0.21 2.9% 0.6%* 
 Composite 6-month endpoint 11.0% 7.9% 0.27 8.0% 7.8% 
  Death 4.4% 2.4% 0.25 3.6% 1.3% 
  In-hospital CHF 3.6% 2.7% 0.56 1.4% 3.9% 
  Rehospitalization for CHF 3.8% 3.1% 0.71 3.7% 2.6% 
 Infarct size (% of left ventricle) 16.0 (3.0, 37.0) (n=25) 24.0 (0.0, 43.0) (n=57) 0.847 24.5 (0.0, 39.0) (n=26) 24.0 (0.0, 49.0) (n=31) 
Late reperfusion therapy      
n 143 278  150 128 
 Death at 1 month 5.6% 6.9% 0.61 7.4% 6.3% 
 Composite 6-month endpoint 13.3% 15.2% 0.60 14.8% 15.6% 
  Death 8.4% 10.1% 0.57 8.7% 11.7% 
  In-hospital CHF 2.8% 2.9% 1.00 4.0% 1.6% 
  Rehospitalization for CHF 4.4% 5.0% 0.77 5.0% 5.0% 
 Infarct size (% of left ventricle) 27.5 (3.5, 50.0) (n=24) 13.5 (0.0, 37.0) (n=58) 0.136 22.5 (2.0, 38.5) (n=32) 8.5 (0.0, 31.0) (n=26) 

*P=0.07 vs. placebo.

Discussion

The major observations of the current analysis are as follows. (i) Consistent with prior reports, patients with anterior AMI who had initiation of reperfusion therapy early (less than the median of 3.17 h) were less likely to develop the composite endpoint of death, new in-hospital CHF, or first rehospitalization for CHF within 6 months compared with patients receiving reperfusion later than the median time. (ii) However, when a 3-h adenosine infusion was administered to patients as an adjunct to reperfusion within 3.17 h of symptom onset, mortality was significantly reduced at 1 and 6 months, and event-free survival was enhanced compared with placebo. (iii) In contrast, patients receiving later initiation of reperfusion therapy did not have a clinical benefit from adenosine. (iv) The benefits of early adenosine administration were observed primarily in patients receiving thrombolytic therapy and to a lesser extent in those with mechanical intervention.

Numerous prior studies of adjunctive therapy in patients with AMI undergoing reperfusion therapy have been performed to improve further clinical outcomes and reduce infarct size.3 Unfortunately, no pharmacologic adjunct has been clearly demonstrated to improve outcomes beyond that achieved by infarct artery recanalization alone, including adjunctive agents assessed for myocardial infarct size reduction by SPECT in the same laboratory (R.J.G) as in the current study. Prior to AMISTAD-II, several smaller studies had suggested that adenosine as an adjunct to reperfusion therapy might reduce infarct size and improve event-free survival.48 In the pivotal AMISTAD-II trial, high-dose (70 µg/kg/min) adenosine in patients with anterior AMI reduced the myocardial infarct size compared with placebo, consistent with the results of the earlier AMISTAD-I trial.1,6 Although there was a strong correlation between infarct size and adverse events in AMISTAD-II, the trial was underpowered to observe reduction in the primary clinical endpoint. Nevertheless, adenosine is one of the few pharmacologic agents that has provided a positive signal for reduction of infarct size in the clinical setting.

The ability of an adjunctive agent to impact positively the prognosis in AMI may depend on the duration of ongoing myocardial injury, as well as the type of reperfusion therapy employed. In this regard, AMISTAD-II enrolled patients with infarct duration up to 6 h before initiation of reperfusion therapy that was either thrombolysis or primary PCI. The results of the present analysis extend the findings of the original study by suggesting that adenosine significantly reduces mortality and improves event-free survival when administered to patients with anterior AMI early in the course of the infarct (within 3.17 h of symptom onset). Moreover, this benefit was observed primarily in patients receiving thrombolytic reperfusion therapy, with a non-significant trend towards a benefit in those undergoing mechanical intervention.

The mechanisms through which adenosine may further improve the prognosis of patients with anterior AMI treated early with thrombolysis is unknown. Potential mechanisms for adenosine's benefit include: an antiplatelet effect that may promote initial or sustained vessel patency;9 coronary vasodilatation, anti-inflammatory effects, and salutary impact on no-reflow;1012 and/or a possible antiarrhythmic effect during post-conditioning as described below. It is known that the thrombolytic therapy itself may activate platelets1316 and hence, an antiplatelet effect of adenosine would potentially be more prominent in the setting of a thrombolytic agent, but may have played some role in the trend towards a benefit in patients receiving angioplasty.

In experimental studies, adenosine can mimic ischaemic pre-conditioning.17 It is unlikely, however, that adenosine's benefit in the present study could have been related to ischaemic pre-conditioning, which necessitates the therapy be administered prior to the ischaemic event. In contrast, a recently described phenomenon called post-conditioning occurs when brief interruptions of reperfusion with short periods of coronary artery occlusion protect the myocardium.18 We have recently observed that post-conditioning has a powerful antiarrhythmic effect, significantly reducing the frequency and duration of ventricular tachycardia in an experimental model of ischaemia/reperfusion. 19 The effect of post-conditioning may be blocked by adenosine antagonists.20 Another recent preclinical study suggests that adenosine production protects the heart from ventricular arrhythmias induced by coronary occlusion.21 Hence, adenosine administered in the peri-reperfusion period, especially with thrombolytic therapy after which transient occlusion and recanalization are frequent22,23 may post-condition the myocardium and possibly reduce lethal ventricular arrhythmias.

The fact that the benefits of adenosine were observed in patients treated within 3 h of symptom onset with thrombolytic therapy suggests a myocardial salvage-dependent mechanism. In contrast, the fact that the low as well as the high dose of adenosine improved clinical outcomes in patients treated early, yet only the high dose reduced infarct size, suggests that the clinical benefits of adenosine may be in part independent of myocardial salvage. This discordance may be due to the small sizes of several of the subsets in the infarct size substudy. A larger confirmatory trial is required both to verify the present results and elucidate the mechanism of benefit of adenosine as an adjunct to thrombolytic therapy in patients presenting early within the course of evolving anterior AMI. Another possibility is that other factors, besides infarct size, contribute to cardiac death post-MIs. These may include post-MI left ventricular remodelling, arrhythmias, degree of inflammation within the infarct vessel or infarcted myocardium, re-occlusion of the infarct vessel, and other factors. Such factors could have played a role in the observation that mortality benefits were observed with both doses of adenosine when combined with early reperfusion but only high-dose appeared to affect infarct size.

There are several limitations of the present analysis. The current study was a post hoc analysis, and the outcomes from subset analyses should not be over interpreted. These results must therefore be considered hypothesis-generating only. Core laboratory angiographic analysis after reperfusion was not performed; and, thus, whether the differential efficacy of adenosine in thrombolytic-treated patients vs. those undergoing PCI might be explained in differences in coronary artery patency or microcirculatory perfusion between the two reperfusion modalities is unknown.

In conclusion, the results of the present analysis suggest that adenosine administered with reperfusion therapy within the first 3.17 h onset of anterior AMI may reduce mortality and enhance freedom from heart failure.

Acknowledgements

Full list of AMISTAD-2 investigators is found in ref. 1. The authors thank Dr King Jolly and Steve Jenkins of King Pharmaceuticals for support with data collection, and Martin Fahy and Yingbo Na of the Cardiovascular Research Foundation in New York, NY, USA, an affiliate of Columbia University Medical Center, for independent statistical analysis.

Conflict of interest: Dr Forman is a co-inventor along with Vanderbilt University of a use patent for adenosine in acute MI.

References

1
Ross
AM
Gibbons
RJ
Stone
GW
Kloner
RA
Alexander
W
for the AMISTAD-II Investigators
A randomized, double-blinded, placebo-controlled multicenter trial of adenosine as an adjunct to reperfusion in the treatment of acute myocardial infarction (AMISTAD-II)
J Am Coll Cardiol
 
2005
45
1775
1780
2
Topol
EJ
Van de Werf
FJ
Topol
E-J
Acute myocardial infarction: early diagnosis and management
Textbook of Cardiovascular Medicine
 
2002
2nd ed.
Philadelphia
Lippincott Williams and Wilkins
385
419
3
Kloner
RA
Rezkalla
SH
Cardiac protection during acute myocardial infarction: where do we stand in 2004?
J Am Coll Cardiol
 
2004
44
276
286
4
Garratt
KN
Holmes
DR
Jr
Molina-Viamonte
V
Reeder
GS
Hodge
DO
Bailey
KR
Lohl
JK
Laudon
DA
Gibbons
RJ
Intravenous adenosine and lidocaine in patients with acute myocardial infarction
Am Heart J
 
1998
136
196
204
5
Marzilli
M
Orsini
E
Marraccini
P
Testa
R
Beneficial effects of intracoronary adenosine as an adjunct to primary angioplasty in acute myocardial infarction
Circulation
 
2000
101
2154
2159
6
Mahaffey
KW
Puma
JA
Barbagelata
NA
DiCarli
MF
Leesar
MA
Browne
KF
Eisenberg
PR
Bolli
R
Casas
AC
Molina-Viamonte
V
Orlandi
C
Blevins
R
Gibbons
RJ
Califf
RM
Granger
CB
Adenosine as an adjunct to thrombolytic therapy for acute myocardial infarction: results of a multicenter, randomized, placebo-controlled trial: the Acute Myocardial Infarction STudy of Adenosine (AMISTAD) trial
J Am Coll Cardiol
 
1999
34
1711
1720
7
Quintana
M
Hjemdahl
P
Sollevi
A
Kahan
T
Edner
M
Rehnqvist
N
Swahn
E
Kjerr
AC
Nasman
P
ATTACC investigators
Left ventricular function and cardiovascular events following adjuvant therapy with adenosine in acute myocardial infarction treated with thrombolysis, results of the ATTenuation by Adenosine of Cardiac Complications (ATTACC) study
Eur J Clin Pharmacol
 
2003
59
1
9
8
Assali
AR
Sdringola
S
Ghani
M
Denkats
AE
Yepes
A
Hanna
GP
Schroth
G
Fujise
K
Anderson
HV
Smalling
RW
Rosales
OR
Intracoronary adenosine administered during percutaneous intervention in acute myocardial infarction and reduction in the incidence of ‘no reflow’ phenomenon
Catheter Cardiovasc Interv
 
2000
51
27
31
9
Hata
K
Whittaker
P
Kloner
RA
Przyklenk
K
Brief antecedent ischemia attenuates platelet mediated thrombus in damaged and stenotic canine coronary arteries: role of adenosine
Circulation
 
1998
97
692
702
10
Olafsson
B
Forman
MB
Puett
DW
Pou
A
Cates
CU
Friesinger
GC
Virmani
R
Reduction of reperfusion injury in the canine preparation by intracoronary adenosine: importance of the endothelium and the no-reflow phenomenon
Circulation
 
1987
76
1135
1145
11
Forman
MB
Velasco
CE
Jackson
EK
Adenosine attenuates reperfusion injury following regional myocardial ischemia
Cardiovasc Res
 
1993
27
9
17
12
Headrick
JP
Hack
B
Ashton
KJ
Acute adenosinergic cardioprotection in ischaemic - reperfused hearts
Am J Physiol Heart Circ Physiol
 
2003
285
H1797
H1818
13
Montrucchio
G
Bergerone
S
Bussolino
F
Alloatti
G
Sivestro
L
Lupia
E
Cravetto
A
DiLeo
M
Emanuelli
G
Camussi
G
Streptokinase induces intravascular release of platelet-activating factor in patients with acute myocardial infarction and stimulates its synthesis by cultured human endothelial cells
Circulation
 
1993
88
1476
1483
14
Kawano
K
Aoki
I
Aoki
N
Homori
M
Maki
A
Hioki
Y
Hasumura
Y
Terano
A
Arai
T
Mizuno
H
Ishikawa
K
Human platelet activation by thrombolytic agents: effects of tissue-type plasminogen activator and urokinase on platelet surface P-selectin expression
Am Heart J
 
1998
135
268
271
15
Fitzgerald
DJ
Catella
F
Roy
L
Fitzgerald
GA
Marked platelet activation in vivo after intravenous streptokinase in patients with acute myocardial infarction
Circulation
 
1988
77
142
150
16
Kerins
DM
Roy
L
Fitzgerald
GA
Fitzgerald
DJ
Platelet and vascular function during thrombolysis with tissue-type plasminogen activator
Circulation
 
1989
80
1718
1725
17
Yao
Z
Gross
GJ
A comparison of adenosine-induced cardioprotection and ischaemic preconditioning in dogs. Efficacy, time course, and role of KATP channels
Circulation
 
1994
89
1226
1236
18
Vinten-Johansen
J
Zhao
ZQ
Zatta
AJ
Kin
H
Halkos
ME
Kerendi
F
Postconditioning. A new link in nature's armor against myocardial ischemia-reperfusion injury
Basic Res Cardiol
 
2005
100
295
310
19
Kloner
RA
Dow
J
Bhandari
A
Postconditioning markedly attenuates ventricular arrhythmias following ischemia/reperfusion
J Cardiovasc Pharmacol Therapeutics
 
2006
11
55
63
20
Yang
X-M
Philipp
S
Downey
JM
Cohen
MV
Postconditioning's protection is not dependent on circulating blood factors or cells but involves adenosine receptors and requires P13-kinase and guanylyl cyclase activation
Basic Res Cardiol
 
2005
100
57
63
21
Collins
HL
DiCarlo
SE
Acute exercise increases the ventricular arrhythmia threshold via the intrinsic adenosine receptor system in conscious hypertensive rats
Am J Physiol Heart Circ Physiol
 
2005
289
H1020
H1026
22
Chen
LY
Nichols
WW
Hendricks
J
Mehta
JL
Myocardial neutrophil infiltration, lipid peroxidation, and antioxidant activity after coronary artery thrombosis and thrombolysis
Am Heart J
 
1995
129
211
218
23
Anderson
JL
Recent clinical developments in thrombolysis in acute myocardial infarction
Drugs
 
1987
33
(Suppl. 3)
22
32

Comments

0 Comments